Abstract
Background: Based on a common belief among people, narcotic substances and psychoactive drugs may help to reduce blood glucose and lipid profile leading to reduced risk of cardiovascular diseases. This hypothesis has been verified in several studies; however, there is no conclusive agreement on the reducing effects of opium and other opioid derivatives on blood glucose and lipids. In the present review, we collected all related literature to evaluate the effects of opioids and psychoactive drugs abuse in altering blood glucose and lipid profile, and discuss their longterm effects.
Methods: A systematic literature search was performed in January 2021 using “lipid profile”, “glucose”, and “opium” including all their equivalents, main derivatives and similar terms. The data were then extracted and reported qualitatively.
Results: Overall, 46 articles with 37407 participants were included after several step–by-step procedures of article selection. Findings of this study suggested that opioids may reduce blood glucose and low-density lipoproteins, while increasing triglyceride. However, these effects are temporary, and long-term substance abuse exacerbates glucose and lipid-associated diseases such as diabetes and atherosclerosis.
Conclusion: Although there are many confounding factors that may affect the results of the included literature; however, based on the findings of these studies, the long-term beneficial effects of opioids on lipid profile and blood glucose cannot be accepted.
Keywords: Opioids, opium, psychoactive drugs, metabolic status, endocrine, blood glucose.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Effects of Opioids and Psychoactive Drugs on Blood Lipid and Glucose Indices; A Systematic Review of Population-Based Evidences
Volume: 21 Issue: 12
Author(s): Azam Rezaei and Maryam Rezaei *
Affiliation:
- Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand,Iran
Keywords: Opioids, opium, psychoactive drugs, metabolic status, endocrine, blood glucose.
Abstract: Background: Based on a common belief among people, narcotic substances and psychoactive drugs may help to reduce blood glucose and lipid profile leading to reduced risk of cardiovascular diseases. This hypothesis has been verified in several studies; however, there is no conclusive agreement on the reducing effects of opium and other opioid derivatives on blood glucose and lipids. In the present review, we collected all related literature to evaluate the effects of opioids and psychoactive drugs abuse in altering blood glucose and lipid profile, and discuss their longterm effects.
Methods: A systematic literature search was performed in January 2021 using “lipid profile”, “glucose”, and “opium” including all their equivalents, main derivatives and similar terms. The data were then extracted and reported qualitatively.
Results: Overall, 46 articles with 37407 participants were included after several step–by-step procedures of article selection. Findings of this study suggested that opioids may reduce blood glucose and low-density lipoproteins, while increasing triglyceride. However, these effects are temporary, and long-term substance abuse exacerbates glucose and lipid-associated diseases such as diabetes and atherosclerosis.
Conclusion: Although there are many confounding factors that may affect the results of the included literature; however, based on the findings of these studies, the long-term beneficial effects of opioids on lipid profile and blood glucose cannot be accepted.
Export Options
About this article
Cite this article as:
Rezaei Azam and Rezaei Maryam *, Effects of Opioids and Psychoactive Drugs on Blood Lipid and Glucose Indices; A Systematic Review of Population-Based Evidences, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (12) : e090821195460 . https://dx.doi.org/10.2174/1871530321666210809155928
| DOI https://dx.doi.org/10.2174/1871530321666210809155928 |
Print ISSN 1871-5303 |
| Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
Call for Papers in Thematic Issues
Advances in Targeting the Gut–Microbiota–Immune Axis in Metabolic Disorders
This special issue aims to explore the rapidly evolving field of the gut–microbiota–immune axis and its critical role in the development, progression, and treatment of metabolic disorders. By highlighting current research and innovative therapeutic strategies, the issue seeks to advance our understanding of how modulating gut microbiota and immune interactions ...read more
Advances in Therapeutic Strategies: Bridging Endocrine, Metabolic, Cancer and Immune Disorders for Precision Medicine.
The intricate interplay between endocrine, metabolic, and immunological disorders, addressing the challenges posed by their overlapping pathophysiology. With a focus on diseases such as diabetes, obesity, autoimmune thyroid conditions, and systemic inflammatory disorders, it highlights the transformative potential of precision medicine. Advances in genomics, transcriptomics, proteomics, and metabolomics are uncovering ...read more
Advancing Therapies for Bone and Joint Diseases: Insights from Natural Products and Herbal Medicines
The aging global population is experiencing an increased risk of bone and joint health issues, notably osteoporosis and osteoarthritis, affecting over half of individuals over 60. Plant-based natural products and herbal medicines are gaining recognition as alternative therapies for these conditions, with secondary metabolites, including flavonoids, coumarins, and others, playing ...read more
Association between Diabetes Mellitus and natural product complementary applications: State of the arts
Diabetes Mellitus (DM) represents a significant global health challenge, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The increasing prevalence of DM, alongside its associated complications, has prompted researchers and healthcare professionals to explore a variety of management strategies beyond conventional pharmacotherapy. Among these ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atherosclerosis and Arterial Blood Pressure in Mice
Current Drug Targets Correlations Between Cerebellar and Brain Volumes, Cognitive Impairments, ApoE Levels, and APOE Genotypes in Patients with AD and MCI
Current Alzheimer Research Past, Present, and Future of Entry Inhibitors as HIV Microbicides
Current HIV Research Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design Hydrogen Sulfide in Inflammation: Friend or Foe?
Inflammation & Allergy - Drug Targets (Discontinued) Alzheimer’s Disease: Erythrocyte 2,3-diphosphoglycerate Content and Circulating Erythropoietin
Current Alzheimer Research An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Dissecting HIV Fusion: Identifying Novel Targets for Entry Inhibitors
Infectious Disorders - Drug Targets Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Current Drug Safety Proteomics Screening of Differentially Expressed Cytokines in Tears of Patients with Graves’ Ophthalmopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiogenin as a Molecular Target for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Developing Practical Therapeutic Strategies that Target Protein SUMOylation
Current Drug Targets Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Current Molecular Medicine Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology The Face of Uncertainty Eats
Current Drug Abuse Reviews Modifiers of Liver-Related Manifestation in the Course of NAFLD
Current Pharmaceutical Design





